Fairvalue-Calculator Fairvalue-Calculator
EN DE

Dr. Martens plc (DOCMF) Fair Value & Analysis

Consumer Cyclical · US · Market cap $928M

Price$0.9700
Fair Value$1.04
Upside+7.2%
Quality97/100
Evidence: High Range $0.6600 – $1.42

Fair value as of: Jun 24, 2026

Analysis

Dr. Martens plc (DOCMF) currently trades at $0.9700, while our model-based Fair Value estimate is $1.04 — implying the stock looks roughly 7.2% undervalued today. We read business quality at 97/100 (high quality), in the Consumer Cyclical sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Dr. Martens plc engages in the design, development, procurement, marketing, sale, and distribution of footwear. The company sells its footwear under the Dr. Martens brand name in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.

Open the full interactive analysis →

Similar stocks

NIKE, Inc (NKE) +22% adidas AG (ADDYY) -36% ASICS Corporation (ASCCY) -25% Deckers Outdoor Corporation (DECK) +64% On Holding (ONON) -44% Zhejiang China Commodities City Group (600415) +150%

Frequently asked questions

Is Dr. Martens plc (DOCMF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.04 versus a price of $0.9700 — about +7% (undervalued). Model-based estimate, not financial advice.
What is the fair value of DOCMF?
Our 21-model fair value for Dr. Martens plc is $1.04 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.9700.
What is the quality score of DOCMF?
Dr. Martens plc has a Quality Score of 97/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.